Contraindications to metformin therapy in patients with Type 2 diabetes—a population‐based study of adherence to prescribing guidelines
- 1 June 2001
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 18 (6) , 483-488
- https://doi.org/10.1046/j.1464-5491.2001.00509.x
Abstract
Aims To define the number of people in Tayside, Scotland (population 349 303) with Type 2 diabetes who use metformin, the incidence of contraindications to its continued use in these people and the proportion that discontinued metformin treatment following the development of a contraindication. Methods Retrospective cohort study of the incidence of contraindications to metformin in all patients with Type 2 diabetes using metformin from January 1993 to June 1995. The contraindications of acute myocardial infarction, cardiac failure, renal impairment and chronic liver disease were identified by: the regional diabetes information system, biochemistry database and hospital admissions database and a database of all encashed community prescriptions. Results One thousand eight hundred and forty seven subjects (26.3% of those with Type 2 diabetes) redeemed prescriptions for metformin. Of these, 3.5% were admitted with an acute myocardial infarction (71 episodes); 4.2% were admitted with cardiac failure (114 episodes); 21.0% received metformin and loop diuretics for cardiac failure concurrently; 4.8% developed renal impairment; and 2.8% developed chronic liver disease. The development of contraindications rarely resulted in discontinuation of metformin, for example only 17.5% and 25% stopped metformin after admission with acute myocardial infarction and development of renal impairment, respectively. In total, 24.5% of subjects receiving metformin, 6.4% of all people with Type 2 diabetes, had contraindications to its use. There was one episode of lactic acidosis in 4600 patient years. Conclusions This population-based study shows that 24.5% of patients prescribed metformin have contraindications to its use. Development of contraindications rarely results in discontinuation of metformin therapy. Despite this, lactic acidosis remains rare. Diabet. Med. 18, 483–488 (2001)Keywords
This publication has 18 references indexed in Scilit:
- Metformin and Lactic Acidosis: Guilt by association?Diabetes Care, 1998
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes registerBMJ, 1997
- Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitusJournal of Clinical Endocrinology & Metabolism, 1996
- MetforminNew England Journal of Medicine, 1996
- Metabolic Effects of Metformin in Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1995
- Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDMDiabetologia, 1994
- Metformin-associated lactic acidosis in Sweden 1977–1991European Journal of Clinical Pharmacology, 1993
- Biguanides and NIDDMDiabetes Care, 1992
- BiguanidesDiabetologia, 1978